FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy
Related Topics >> voluntary recall | ADHD | Patches | Daytrana | Shire

Shire recalls ADHD drug patches

Drug patches have had a tough time lately, with recalls coming on everything from too-tight adhesive to slits in active-ingredient reservoirs. Today, the recalled patch in the news is Shire's Daytrana, an attention deficit hyperactivity disorder med. Two lots were withdrawn on concerns about the patch's liner, which could be difficult for patients to remove before applying the patch. Shire recalled a limited number of patches for the same reason just a year ago.

Shire sells the patches on license from Noven Pharmaceuticals, which sent out a statement saying that it has identified the "definitive root cause" of the defect and is now "aggressively testing potential solutions."

- read the Associated Press article

Related Articles:
Another company recalls fentanyl patch
Mylan steps into pain-patch void
AHA: Kids need EKG before ADHD meds
FDA approves Lilly's ADHD drug Strattera

More stories about voluntary recall   ADHD   Patches   Daytrana   Shire  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 9 + 0?
To combat spam, please solve the math question above.